OxThera is currently backed by a syndicate of well known investors with a strong international footprint and an extensive history of successful investments within the biotech industry.
OxThera has attracted a consortium of experienced investors. Additionally, the company has been able to secure non-dilutive funding and grants to support its R&D operations. The list of current owners include:
LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s, the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1.7 billion ($2.0 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. The LSP Health Economics Fund 2 invests in innovative products that can increase the quality of health care, while reducing the cost of care.
Industrifonden is an independent evergreen venture capital fund focusing on technology and life science companies. The fund has close to tripled in size since its inception, following profitable exits in many different sectors. As an evergreen fund, we have a unique position. If we believe that a company will be worth substantially more a few years down the road, we have the patience and commitment necessary to keep backing it.
Kurma Partners is a key European player in the financing of innovation in healthcare and biotechnology, notably through Kurma Biofund I and II, Kurma Diagnostics and strategic partnerships with prestigious European research and medical institutions.
Sunstone Life Science Ventures
Sunstone Life Science Ventures’ is a European, early-stage investor based in Copenhagen. We have a focus on investment opportunities in the therapeutics field, and we typically make our initial investment in companies raising Series A/B rounds, but we may invest at an earlier stage.
At Sunstone we are passionate about being part of the journey where science is turned into products benefiting patients worldwide. We seek opportunities which improve patient outcome and have the potential of offering solutions that are more efficient for the health care system.
Our team brings together a diverse set of professional experience: from entrepreneurial ventures to corporate management and financial services. Our background allows us to support our portfolio companies on a breadth of issues, providing a 360° approach, ranging from high strategic level to specific operational issues.
We believe that the founder/investor relationship works best when built on a balanced foundation of respect and honesty. Building a successful start-up is rarely a straightforward process, and most companies experience troubles at some point in time. In that situation, everyone is best served by having an honest and collaborative relationship.
Ysios Capital is a leading Spanish venture capital firm that provides private equity financing to early- and mid-stage human healthcare and life science companies with a special focus on pharmaceuticals, diagnostics and medical devices. Founded in 2008, Ysios Capital currently manages about €200M ($220M) distributed across two funds: Ysios BioFund I, fully invested, and Ysios BioFund II Innvierte.